Brief: Infinity Pharmaceuticals Provides Update For Eganelisib In Patients With Metastatic Urothelial Cancer
06/01/2021 14:26
Jan 6 (Reuters) - Infinity Pharmaceuticals Inc INFI.O :
* INFINITY PHARMACEUTICALS PROVIDES UPDATE FOR EGANELISIB IN
PATIENTS WITH METASTATIC UROTHELIAL CANCER
* INFINITY PHARMACEUTICALS INC - MARIO-275 DATA TO BE
PRESENTED AT
A MAJOR MEDICAL MEETING IN Q1 2021
* INFINITY PHARMACEUTICALS - PLANNING NEW STUDY IN ADVANCED
UROTHELIAL CANCER LEVERAGING ENCOURAGING DATA FROM MARIO-275
* INFINITY- CO EXPECTS TO HAVE CASH THROUGH 2021 BASED ON
ITS
CURRENT OPERATING PLANS, EXCLUDING ADDITIONAL FINANCING OR
BUSINESS ACTIVITIES
* INFINITY - 2021 CASH GUIDANCE ALSO EXCLUDES POTENTIAL $5
MILLION
MILESTONE PAYMENT FROM BVF & ANY MILESTONES FROM OR SALE OF CO'S
EQUITY IN PELLEPHARM
Source text for Eikon: ID:nBw1Z2ksfa
Further company coverage: INFI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Infinity Pharmaceuticals
See all newsBrief: Infinity Pharmaceuticals Filed Voluntary Petition For Relief Under Provisions Of Chapter 11
Brief: Infinity Pharmaceuticals Inc Received Determination Letter From Nasdaq On September 12
Brief: Infinity Pharma Says On Sept 5, 2023, Co Received Letter From Nasdaq Notifying That Listing Of Common Stock Was Not In Compliance With Nasdaq Listing Rule
Brief: Infinity Pharmaceuticals Approved Plan To Reduce Co's Overall Headcount By 21 Positions
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX